Comparative Pharmacology
Head-to-head clinical analysis: LEUPROLIDE ACETATE FOR DEPOT SUSPENSION versus TRELSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEUPROLIDE ACETATE FOR DEPOT SUSPENSION versus TRELSTAR.
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION vs TRELSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Continuous administration suppresses pituitary gonadotropin secretion, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing gonadal steroid production (testosterone and estrogen).
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced testicular and ovarian steroidogenesis.
3.75 mg IM every 4 weeks or 11.25 mg IM every 12 weeks for advanced prostate cancer; 3.75 mg IM every month for endometriosis or uterine leiomyomas; 7.5 mg IM monthly for central precocious puberty.
3.75 mg intramuscularly once every 4 weeks or 11.25 mg intramuscularly once every 12 weeks or 22.5 mg intramuscularly once every 24 weeks.
None Documented
None Documented
3-4 hours for subcutaneous injection; after depot injection, initial burst release followed by slow release with apparent half-life of approximately 3-4 weeks due to absorption rate-limited elimination.
Terminal elimination half-life approximately 3 weeks (21-28 days) after intramuscular injection; sustained release formulation results in prolonged exposure.
Primarily renal (metabolites), approximately 5% unchanged; fecal elimination accounts for <5%.
Primarily hepatic metabolism; <5% excreted unchanged in urine; fecal elimination of metabolites accounts for approximately 20-30%.
Category D/X
Category C
GnRH Agonist
GnRH Agonist